Clarion Elects Mark Altmeyer to its Board of Directors
Boston, MA – Clarion Healthcare (“Clarion”), a leading life sciences strategy and organizational consultancy, announced that Mark Altmeyer has joined its Board of Directors. Mr. Altmeyer, who was most recently the President and Chief Executive Officer (CEO) at Arvelle Therapeutics, has 30 years of experience leading successful global drug commercialization efforts across a broad set of therapeutic areas and geographies.
“We are thrilled to welcome Mark as a Board Member,” said Tom Murtagh, Clarion CEO and Founder. “Mark brings deep insight into the factors impacting global commercialization efforts and will be a great resource to the Clarion team as we continue to invest in and build Clarion’s global focus. Mark’s appreciation for the client-side will further help Clarion hone its longstanding commitment to being the “fit-for purpose” strategic partner of choice for global commercialization decision-making and operationalization.”
“Mark is an outstanding choice to join the Clarion Board,” shared John Svoboda, co-founder of Svoboda Capital Partners LLC. “He is the rare combination of seasoned industry veteran, voice of the customer, entrepreneur and international business builder – all elements that are key to supporting Clarion’s ambitious growth strategy.”
Prior to starting Arvelle Therapeutics, Mark was the President and Chief Commercial Officer (CCO) of Axovant Sciences, where he led the establishment of the global commercial capabilities and product launch preparations as well as establishing and building out a global headquarters in Switzerland. He was also previously the CEO and President of Otsuka America Pharmaceutical, Inc., where he led a team of 1,700 employees and helped grow the company’s revenue from $2.6 billion to over $5 billion. He led the launch of Abilify®, the top-selling CNS drug in history and the number-one selling drug in the United States in 2013. Earlier in his career, Mark held executive leadership roles at Bristol-Myers Squibb, including Senior Vice President, Global Commercialization for Neuroscience and Oncology, and Senior Vice President, Neuroscience Business Unit. Mark received an MBA from Harvard Business School and a BA in economics from Middlebury College.
Clarion is a life sciences strategy and organizational consultancy that works together with its clients to Envision, Craft, and Enable growth through innovation and leadership. Across therapeutic categories, Clarion collaborates deeply with its clients to tackle their most complex cross-functional business challenges and decisions throughout the product and company lifecycle. From start-up to global multinational companies, Clarion helps assemble and deliver inspired strategies that require creativity, insight, and collaboration. Clarion builds leaders across the industry.